- Report
- December 2024
- 68 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- May 2024
- 134 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- June 2024
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- October 2021
- 104 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- August 2022
Global
From €719EUR$790USD£616GBP
- Report
- May 2022
- 38 Pages
Global
From €1820EUR$2,000USD£1,560GBP
The Polymyositis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Polymyositis is an inflammatory disorder that affects the muscles, causing muscle weakness and pain. Treatment for this condition typically involves a combination of medications, physical therapy, and lifestyle changes. Common medications used to treat polymyositis include corticosteroids, immunosuppressants, and biologics.
The Polymyositis Drug market is highly competitive, with a number of companies offering products for the treatment of this condition. Companies in this market include AbbVie, Amgen, Biogen, Celgene, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. These companies are engaged in research and development of new drugs and therapies for the treatment of polymyositis. Show Less Read more
